Introduction The treatment of patients with metastatic breast cancer (mBC) is one of the most
difficult problems in clinical oncology. Clinical trial results suggest that novel therapies may …

Purpose Diagnosis and treatment of breast cancer have changed profoundly over the past
25 years. The outcome improved dramatically and was well quantified for early stage breast …

Background Although survival of patients with metastatic breast cancer (MBC) has been
significantly prolonged over the past decade due to improvement of anti-cancer …

Approximately 6% of patients with breast cancer have distant metastases at the time of the
initial diagnosis. The aim of this analysis was to examine the overall survival rate over time …

Metastatic breast cancer (MBC) remains an incurable disease, despite major advances in
the treatment in the past 10–12 years. Data on real life overall survival in a non-selected …

Background Early detection and improved (neo)-adjuvant treatment has extended survival of
breast cancer over the last decades. It remains controversial whether a survival benefit is …

BACKGROUND The expectation of improvement in patient survival with administration of
new chemotherapy agents for metastatic breast carcinoma (MBC) is not consistently …

Introduction Metastatic breast cancer (MBC) is a life-threatening disease, and although
some data suggest a trend in survival improvement, it has not yet been unequivocally …

Background: Treatment of metastatic breast cancer (MBC) remains palliative. Patients with
MBC represent a heterogeneous group whose prognosis and outcome may be dependent …

Metastatic breast cancer (MBC) is hard to cure by the therapies currently available and
median long-term survival in MBC has been reported as either 18–24 months [1] or 2–4 …